Insulet Corporation $PODD Shares Sold by Yousif Capital Management LLC

Yousif Capital Management LLC reduced its stake in shares of Insulet Corporation (NASDAQ:PODD) by 3.0% in the 2nd quarter, HoldingsChannel reports. The institutional investor owned 11,064 shares of the medical instruments supplier’s stock after selling 339 shares during the quarter. Yousif Capital Management LLC’s holdings in Insulet were worth $3,476,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. Zions Bancorporation National Association UT acquired a new stake in shares of Insulet during the first quarter worth $26,000. Larson Financial Group LLC lifted its stake in shares of Insulet by 426.3% during the first quarter. Larson Financial Group LLC now owns 100 shares of the medical instruments supplier’s stock worth $26,000 after buying an additional 81 shares during the period. SouthState Corp lifted its stake in shares of Insulet by 253.3% during the first quarter. SouthState Corp now owns 106 shares of the medical instruments supplier’s stock worth $28,000 after buying an additional 76 shares during the period. Kozak & Associates Inc. acquired a new stake in shares of Insulet during the second quarter worth $32,000. Finally, Trust Co. of Toledo NA OH acquired a new stake in shares of Insulet during the second quarter worth $35,000.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on PODD shares. Citigroup restated a “buy” rating on shares of Insulet in a research report on Tuesday, July 8th. Wells Fargo & Company boosted their target price on shares of Insulet from $330.00 to $350.00 and gave the company an “overweight” rating in a research report on Friday, August 8th. Royal Bank Of Canada boosted their target price on shares of Insulet from $350.00 to $365.00 and gave the company an “outperform” rating in a research report on Friday, October 10th. Weiss Ratings restated a “hold (c)” rating on shares of Insulet in a research report on Wednesday, October 8th. Finally, The Goldman Sachs Group decreased their target price on shares of Insulet from $399.00 to $375.00 and set a “buy” rating for the company in a research report on Wednesday, October 1st. One investment analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Insulet presently has a consensus rating of “Moderate Buy” and an average target price of $348.05.

Insulet Trading Up 1.2%

Shares of Insulet stock opened at $316.29 on Friday. The firm has a 50-day simple moving average of $325.99 and a two-hundred day simple moving average of $301.60. The company has a market cap of $22.26 billion, a P/E ratio of 96.14, a price-to-earnings-growth ratio of 2.61 and a beta of 1.40. Insulet Corporation has a fifty-two week low of $226.50 and a fifty-two week high of $353.50. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.81 and a current ratio of 2.26.

Insulet (NASDAQ:PODD) last issued its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share for the quarter, topping analysts’ consensus estimates of $0.92 by $0.25. The business had revenue of $649.10 million during the quarter, compared to the consensus estimate of $612.31 million. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The company’s revenue was up 32.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.55 earnings per share. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. As a group, equities analysts predict that Insulet Corporation will post 3.92 earnings per share for the current fiscal year.

Insider Transactions at Insulet

In other news, SVP Laetitia Cousin sold 797 shares of the business’s stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $348.81, for a total transaction of $278,001.57. Following the completion of the sale, the senior vice president owned 3,890 shares of the company’s stock, valued at $1,356,870.90. The trade was a 17.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, SVP Prem Singh sold 687 shares of the business’s stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $347.49, for a total transaction of $238,725.63. Following the sale, the senior vice president directly owned 3,456 shares of the company’s stock, valued at $1,200,925.44. This represents a 16.58% decrease in their position. The disclosure for this sale can be found here. 0.39% of the stock is owned by insiders.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.